HIV Research for Prevention Conference, HIVR4P 2020

项目摘要 艾滋病毒的流行控制是可行的，但前提是我们必须大力加强我们在#年的初级预防工作。 青少年和成年人处于危险之中，并确保制定下一代预防方法。而当 在扩大有效的生物医学预防和补充方面取得了很大进展 行为和结构方法，一些群体和地区的新感染，包括在 在美国，这一数字不仅没有下降，反而在上升。最多五次新药疗效试验的结果 预防技术预计在2020/21年度，预防领域将面临艰难的决定，持怀疑态度和 不堪重负的实施受众和质疑社区。在这种背景下，艾滋病毒 2020年预防研究大会(HIVR4P 2020)将是关键的全球科学会议，以反映 关于艾滋病毒预防的状况，重新调整优先事项，并制定未来十年的工作计划。这个 会议将批判性地评估疫苗开发的最新研究成果，单抗 干预措施、PrEP和其他基于ARV的方法、长效和仓库配方、其他新技术 预防模式和相关的执行科学。于11日在南非开普敦举行 到2020年10月15日，HIVR4P 2020将有来自50多个国家的1,400名代表出席。 南非继续在产品开发和测试方面发挥重要作用， 美国。因此，在开普敦参加HIVR4P将使代表们有机会受益于 了解在这一关键环境中的成功和挑战，同时参与广泛的科学和 来自美国、欧洲、亚洲和其他地区的专家与非洲同行进行政策交流。 HIVR4P 2020的具体目标是： 1.召集艾滋病毒预防和相关领域的世界专家，以促进科学知识，介绍 新的研究成果，并加强全球科学和社区合作； 2.推进以证据为基础和以人权为基础的艾滋病毒预防，以满足以下需要 尤其是高危和弱势群体，以减少健康差距，包括：青少年和青年 成年人、高负担环境中的妇女和女孩、流离失所人口、男男性行为者、 囚犯和其他被监禁的人、吸毒者、性工作者和变性人； 3.完善艾滋病毒预防研究议程，以反映已查明的机会和知识差距，包括： 下一代艾滋病毒疫苗和bNAbs；更智能的分子递送系统，包括更长的- 代理和多用途技术；PrEP进一步推广和长期推广的挑战和机遇 准备使用；将性传播感染(STI)和艾滋病毒预防纳入更广泛的性传播和 生殖健康办法；在改变阿片类药物使用模式的背景下预防艾滋病毒；以及 跨越疾病和风险领域的综合预防议程。 科学计划将围绕五个主题领域展开：基础科学、PREP和以抗逆转录病毒为基础的 预防；疫苗和bNAbs临床试验；其他预防方式和交叉问题；以及 应用科学和实施学。将在全体会谈中强调交叉方面，还 将科学轨道与社区和领导力观点联系起来。年轻人的参与 通过积极征集研究人员、基础科学家和相关领域的研究人员 相关的科学和提供具体的资金支持。免费远程访问会议 演示文稿和海报以及强大的社交媒体传播将确保覆盖范围超出那些有能力的人 亲自出席并参加现场讨论。

Project Summary Epidemic control of HIV is feasible but only if we substantially strengthen our primary prevention efforts in adolescents and adults at risk and ensure the development of next-generation prevention methods. While much progress has been made in expanding effective biomedical prevention and in complementary behavioral and structural approaches, new infections in some groups and geographies, including in the United States, are not declining but are on the rise. With the results of up to five efficacy trials of new prevention technologies expected in 2020/21, the prevention field will face difficult decisions, skeptical and overburdened implementation audiences, and questioning communities. Against this background, the HIV Research for Prevention Conference 2020 (HIVR4P 2020) will be the key global scientific convening to reflect on the state of HIV prevention, recalibrate priorities, and map out a workplan for the coming decade. The conference will critically assess the latest research results in vaccine development, monoclonal antibody interventions, PrEP and other ARV-based approaches, long-acting and depot formulations, other novel prevention modalities, and relevant implementation science. Taking place in Cape Town, South Africa, on 11 to 15 October 2020, HIVR4P 2020 will have an attendance of 1,400 delegates from more than 50 countries. South Africa continues to play a significant role in product development and testing in cooperation with the United States. Attending HIVR4P in Cape Town will thus offer delegates the opportunity to benefit from learning about the successes and challenges in this critical setting while engaging in a broad scientific and policy exchange between specialists from the U.S, Europe, Asia and other regions with their African peers. The specific aims of HIVR4P 2020 are to: 1. Convene the world’s experts in HIV prevention and related fields to advance scientific knowledge, present new research findings, and enhance global scientific and community collaborations; 2. Advance evidence-informed and human rights-based HIV prevention that is tailored to the needs of particularly at risk and vulnerable groups to reduce health disparities including: adolescents and young adults, women and girls in high-burden settings, displaced populations, men who have sex with men, prisoners and other incarcerated people, people who use drugs, sex workers, and transgender people; 3. Refine HIV prevention research agendas to reflect identified opportunities and knowledge gaps, including: next generation of HIV vaccines and bNAbs; smarter delivery systems for molecules, including longer- acting and multi-purpose technologies; challenges and opportunities of further PrEP roll-out ad long-term PrEP use; integrated sexually transmitted infections (STI) and HIV prevention within broader sexual and reproductive health approaches; HIV prevention in the context of changing patterns of opioid use; and integrated prevention agendas that cut across disease and risk areas. The scientific program will be structured along five thematic areas: Basic science; PrEP and ARV-based prevention; Vaccines and bNAbs clinical trials; Other prevention modalities and cross-cutting issues; and Applied and implementation science. Cross-cutting aspects will be highlighted in plenary talks that also connect the scientific tracks with community and leadership perspectives. The participation of young researchers, basic scientists and researchers in related fields will be strengthened by active solicitation of relevant science and the provision of specific financial support. Free remote access to conference presentations and posters and robust social media dissemination will ensure reach beyond those able to attend in person and join the discussions on site.